Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study

INTRODUCTION: Patients receiving cardiorenal-protective renin–angiotensin–aldosterone system inhibitors (RAASis) are at increased risk of developing hyperkalemia, which is associated with increased medical costs. The aim of this study was to evaluate the impact of adding sodium zirconium cyclosilica...

Descripción completa

Detalles Bibliográficos
Autores principales: Dwyer, Jamie P., Agiro, Abiy, Desai, Pooja, Oluwatosin, Yemisi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567937/
https://www.ncbi.nlm.nih.gov/pubmed/37606716
http://dx.doi.org/10.1007/s12325-023-02631-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10567937/
https://www.ncbi.nlm.nih.gov/pubmed/37606716
http://dx.doi.org/10.1007/s12325-023-02631-w

Ejemplares similares